Stay updated with breaking news from Nasdaq Bcyc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) have earned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 2,960,000 shares, a growth of 16.5% from the March 31st total of 2,540,000 shares. Based on an average daily volume of 399,400 shares, the days-to-cover ratio […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Get Free Report) CEO Kevin Lee sold 3,158 shares of the business’s stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $23.81, for a total value of $75,191.98. Following the transaction, the chief executive officer now directly owns 387,270 shares […]
Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) released its earnings results on Tuesday. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.07, reports. The firm had revenue of $5.33 million during the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative […]
Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) – Equities research analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for Bicycle Therapeutics in a note issued to investors on Tuesday, February 20th. Leerink Partnrs analyst J. Chang forecasts that the company will earn ($5.20) per share for the year. The consensus estimate for […]